Summary: We developed the STOPGAP (Systematic Target OPportunity assessment by Genetic Association Predictions) database, an extensive catalog of human genetic associations mapped to effector gene candidates. STOPGAP draws on a variety of publicly available GWAS associations, linkage disequilibrium (LD) measures, functional genomic and variant annotation sources. Algorithms were developed to merge the association data, partition associations into nonoverlapping LD clusters, map variants to genes and produce a variant-to-gene score used to rank the relative confidence among potential effector genes. This database can be used for a multitude of investigations into the genes and genetic mechanisms underlying inter-individual variation in human traits, as well as supporting drug discovery applications. Availability and implementation: Shell, R, Perl and Python scripts and STOPGAP R data files (version 2.5.1 at publication) are available at https://github.com/StatGenPRD/STOPGAP. Some of the most useful STOPGAP fields can be queried through an R Shiny web application at
Introduction
Human genetic evidence is an important source of causal evidence connecting drug targets and disease indications. Recent studies have shown that drug programs with targets having human genetic evidence are less likely to fail throughout the drug discovery and development pipeline. We recently showed that drug mechanisms with the support of genetic evidence were twice as likely to succeed as those without it (Nelson et al., 2015) .
Genome-wide association studies (GWAS) conducted over the past decade provide a growing body of evidence providing causal relationships between genetic variation and a wide range of human traits and diseases. The GWAS Catalog (Welter et al., 2014) was established as a manually curated central repository to capture the associated loci discovered in published GWAS, generally represented by the single variant within each locus with the smallest p-value. The greatest limitation in applying new biological understanding from these loci is the gene through which the genetic variants are exerting their effect, i.e. the effector gene, is unknown. It is estimated that only about 4.9% of genetic associations discovered by GWAS are the result of a change in the protein sequence (Maurano et al., 2012) . Variants that affect gene regulation can be located upstream or downstream of a transcription start site (TSS), and although most likely near the TSS, may be located 100s of kilobases away (Claussnitzer et al., 2015) . The recent explosion of available Applications Note functional genomics data such as the ENCODE, chromatin contact maps and eQTLs that can enable the mapping of genetically associated variants to plausible effector genes. To facilitate investigations into the genes most likely to influence human disease, we developed STOPGAP (Systematic Target OPportunity assessment by Genetic Association Predictions), a database of genetic associations mapped to candidate effector genes based on linkage disequilibrium (LD), functional genomic and other annotation resources.
Approach and results
The data integration and annotation strategy we used is shown in Figure 1 and the detailed integration workflow is in Supplementary Figure S1 . The latest version of STOPGAP integrates five GWAS sources including GWAS Catalog, GRASP, GWASdb, selected recent literature yet to be included in the GWAS Catalog, and the BioVU PheWAS (see the Supplementary Materials for references and links to data), retaining associations with P-values 10 À4 .
All variants in linkage disequilibrium (LD) having an r 2 ! 0.7
with each associated variant were identified based on the 1000
Genomes Project phase 1 sequence genotypes from the European populations (N ¼ 379) and included as candidate causal variants. The combined set of variants were mapped into disjoint LD clusters (Supplementary Materials), which roughly represent independent groups of associated loci across the genome. Each variant was then annotated and mapped to potential effector genes as summarized in Figure 1 , creating a dataset with every possible variant to gene mapping for every associated and LD variant with a score for the relative mapping strength. To ease use of this database, we created two further levels of aggregation. The first derivative retains the mapping with the highest gene score for each reported association for each mapped gene. The second derivative retains the highest gene score for each MeSH-mapped trait and gene combination. The genetic associations merged from the five sources are summarized in Supplementary Table S2 . In total, there are 352 101 index SNP associations, of which 23.2% have P-values 10 À8 (considered genome-wide significant). Index SNPs are representative of the association within a locus. The 81 589 significant associations correspond to 1925 unique traits (as reported) and 467 unique MeSH terms from 1803 publications. Of the significant associations included, 11.1% are from GWAS catalog, while 74.4%, 7.1%, 7.4% and <0.1% are from GRASP, GWASdb, recent literature and BioVU PheWAS data, respectively. About 98% of associated variants are mapped to at least one protein-coding gene based on GENCODE genes mapped to GRCh37. The most aggregated dataset (stopgap.gene.mesh), corresponding to one entry for every genetrait combination observed, is summarized in Table 1 . Overall, 16.3% of GWAS SNPs reach a conservative level of genome-wide significance with p-value 10 À8 . However, GWAS SNPs in LD with one or more variants with functional mapping evidence are more likely to be genome-wide significant (14.6 to 21.7%). These datasets can be used for various purposes including directly supporting drug target selection, validation and repositioning decisions. Please refer to the Supplementary Materials for details, summary statistics and the scripts used to implement the database. The database version described here is 2.5.1. Updates to the input genetic association results and methods improvements are made every four to six months with code and data updates posted on the Github site. 
